间充质干细胞治疗冠状病毒（COVID-19）引起的肺炎：带着新希望重新审视旁分泌假说？
Mesenchymal Stem Cells for Coronavirus (COVID-19)-Induced Pneumonia: Revisiting the Paracrine Hypothesis with New Hopes?
作者信息
Öztürk Selçuk, Elçin Ayşe Eser, Elçin Yaşar Murat
机构信息
Tissue Engineering, Biomaterials and Nanobiotechnology Laboratory, Faculty of Science, Ankara University, Ankara, Turkey.
出版信息
Aging Dis. 2020 May 9;11(3):477-479. doi: 10.14336/AD.2020.0403. eCollection 2020 May.
Abstract
Mesenchymal stem cells (MSCs) bear a promising potential for regenerative medicine therapies and they repair damaged tissue through secretion of immune modulatory and anti-inflammatory molecules acting in a paracrine fashion. Coronavirus disease 2019 (COVID-19) has spread all over the world with high morbidity and mortality rates and there is no specific treatment for this infection. A recent study published in the journal reports that MSC infusion is safe and effective in patients suffering from COVID-19 induced pneumonia. In the light of this study and previous reports, we make additional comments about possible therapeutic effects of MSCs in COVID-19 infection.
摘要
间充质干细胞（MSCs）在再生医学治疗方面具有广阔的应用前景，它们通过以旁分泌方式分泌免疫调节和抗炎分子来修复受损组织。2019冠状病毒病（COVID-19）已在全球范围内传播，发病率和死亡率都很高，且尚无针对这种感染的特效治疗方法。最近发表在该杂志上的一项研究报告称，输注间充质干细胞对感染COVID-19所致肺炎的患者是安全有效的。鉴于这项研究及先前的报道，我们对间充质干细胞在COVID-19感染中的潜在治疗作用作进一步评论。
相似文献
1
Mesenchymal Stem Cells for Coronavirus (COVID-19)-Induced Pneumonia: Revisiting the Paracrine Hypothesis with New Hopes?间充质干细胞治疗冠状病毒（COVID-19）引起的肺炎：带着新希望重新审视旁分泌假说？
Aging Dis. 2020 May 9;11(3):477-479. doi: 10.14336/AD.2020.0403. eCollection 2020 May.
2
Mesenchymal Stem Cell Infusion Shows Promise for Combating Coronavirus (COVID-19)- Induced Pneumonia.间充质干细胞输注显示出对抗冠状病毒（COVID-19）诱发肺炎的潜力。
Aging Dis. 2020 Mar 9;11(2):462-464. doi: 10.14336/AD.2020.0301. eCollection 2020 Apr.
3
Mesenchymal stem cell-based therapy and exosomes in COVID-19: current trends and prospects.基于间充质干细胞的治疗和细胞外囊泡在 COVID-19 中的应用：当前趋势和前景。
Stem Cell Res Ther. 2021 Aug 21;12(1):469. doi: 10.1186/s13287-021-02542-z.
4
Mechanisms of Potential Therapeutic Utilization of Mesenchymal Stem Cells in COVID-19 Treatment.间充质干细胞在 COVID-19 治疗中的潜在治疗应用机制。
Cell Transplant. 2023 Jan-Dec;32:9636897231184611. doi: 10.1177/09636897231184611.
5
Therapeutic Properties of Mesenchymal Stromal/Stem Cells: The Need of Cell Priming for Cell-Free Therapies in Regenerative Medicine.间质基质/干细胞的治疗特性：再生医学中细胞无细胞治疗需要细胞预刺激。
Int J Mol Sci. 2021 Jan 14;22(2):763. doi: 10.3390/ijms22020763.
6
MSC Therapies for COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product Quality and Mode of Delivery for Treatment Safety and Efficacy.MSC 疗法治疗 COVID-19：患者凝血病、血栓预防、细胞产品质量和治疗安全性及疗效的输送方式的重要性。
Front Immunol. 2020 May 19;11:1091. doi: 10.3389/fimmu.2020.01091. eCollection 2020.
7
The roles of mesenchymal stem cells in tissue repair and disease modification.间充质干细胞在组织修复和疾病修饰中的作用。
Curr Stem Cell Res Ther. 2014;9(5):424-31. doi: 10.2174/1574888x09666140616125446.
8
Anti-inflammatory Effects of Mesenchymal Stem Cells and their Secretomes in Pneumonia.间充质干细胞及其分泌产物在肺炎中的抗炎作用
Curr Pharm Biotechnol. 2022;23(9):1153-1167. doi: 10.2174/1389201022666210907115126.
9
10
Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients with Acute Respiratory Distress Syndrome (ARDS).用于治疗新冠肺炎急性呼吸窘迫综合征（ARDS）患者的脐带间充质干细胞
CellR4 Repair Replace Regen Reprogram. 2020;8. doi: 10.32113/cellr4_20204_2839. Epub 2020 Apr 28.
引用本文的文献
1
Clinical Trials of Mesenchymal Stem Cells for the Treatment of COVID 19.间充质干细胞治疗 COVID-19 的临床试验。
Curr Stem Cell Res Ther. 2024;19(8):1055-1071. doi: 10.2174/011574888X260032230925052240.
2
Advances in Regenerative Medicine and Biomaterials.再生医学和生物材料的进展。
Methods Mol Biol. 2023;2575:127-152. doi: 10.1007/978-1-0716-2716-7_7.
3
Safety and long-term improvement of mesenchymal stromal cell infusion in critically COVID-19 patients: a randomized clinical trial.间充质基质细胞输注对危重型 COVID-19 患者的安全性及长期改善效果：一项随机临床试验
Stem Cell Res Ther. 2022 Mar 21;13(1):122. doi: 10.1186/s13287-022-02796-1.
4
Stem cell therapy for COVID-19 pneumonia.新冠肺炎的干细胞治疗
Mol Biomed. 2022 Feb 17;3(1):6. doi: 10.1186/s43556-021-00067-8.
5
Potency of Mesenchymal Stem Cell and Its Secretome in Treating COVID-19.间充质干细胞及其分泌组在治疗新型冠状病毒肺炎中的效力
Regen Eng Transl Med. 2022;8(1):43-54. doi: 10.1007/s40883-021-00202-5. Epub 2021 Mar 10.
6
Efficacy of mesenchymal stromal cells and cellular products in improvement of symptoms for COVID-19 and similar lung diseases.间充质基质细胞和细胞产品在改善 COVID-19 和类似肺部疾病症状方面的功效。
Biotechnol Bioeng. 2021 Jun;118(6):2168-2183. doi: 10.1002/bit.27729. Epub 2021 Mar 27.
7
Therapeutic Applications of Stem Cells and Extracellular Vesicles in Emergency Care: Futuristic Perspectives.干细胞和细胞外囊泡在急救护理中的治疗应用：未来展望。
Stem Cell Rev Rep. 2021 Apr;17(2):390-410. doi: 10.1007/s12015-020-10029-2.
8
The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: What to expect.在 COVID-19 相关急性呼吸窘迫综合征患者中使用间充质干细胞的基本原理：预期会有什么结果。
Stem Cells Transl Med. 2020 Nov;9(11):1287-1302. doi: 10.1002/sctm.20-0164. Epub 2020 Jul 21.
9
Potential Using of Fat-derived Stromal Cells in the Treatment of Active Disease, and also, in Both Pre- and Post-Periods in COVID-19.脂肪来源的基质细胞在治疗活动性疾病以及COVID-19的前期和后期的潜在应用。
Aging Dis. 2020 Jul 23;11(4):730-736. doi: 10.14336/AD.2020.0621. eCollection 2020 Jul.
10
Mesenchymal Stem Cells in COVID-19: A Journey from Bench to Bedside.新型冠状病毒肺炎中的间充质干细胞：从基础到临床的探索。
Lab Med. 2021 Jan 4;52(1):24-35. doi: 10.1093/labmed/lmaa049.
本文引用的文献
1
Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: A case report.人脐带间充质干细胞治疗危重症新型冠状病毒肺炎患者临床缓解一例报告
Medicine (Baltimore). 2020 Jul 31;99(31):e21429. doi: 10.1097/MD.0000000000021429.
2
Mesenchymal Stem Cell Infusion Shows Promise for Combating Coronavirus (COVID-19)- Induced Pneumonia.间充质干细胞输注显示出对抗冠状病毒（COVID-19）诱发肺炎的潜力。
Aging Dis. 2020 Mar 9;11(2):462-464. doi: 10.14336/AD.2020.0301. eCollection 2020 Apr.
3
Transplantation of ACE2 Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia.血管紧张素转换酶2间充质干细胞移植改善新型冠状病毒肺炎患者的预后。
Aging Dis. 2020 Mar 9;11(2):216-228. doi: 10.14336/AD.2020.0228. eCollection 2020 Apr.
4
World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19).世界卫生组织宣布全球紧急状态：对 2019 年新型冠状病毒（COVID-19）的回顾。
Int J Surg. 2020 Apr;76:71-76. doi: 10.1016/j.ijsu.2020.02.034. Epub 2020 Feb 26.
5
A Novel Coronavirus Emerging in China - Key Questions for Impact Assessment.一种在中国出现的新型冠状病毒——影响评估的关键问题
N Engl J Med. 2020 Feb 20;382(8):692-694. doi: 10.1056/NEJMp2000929. Epub 2020 Jan 24.
6
Mesenchymal stem cells-derived extracellular vesicles in acute respiratory distress syndrome: a review of current literature and potential future treatment options.急性呼吸窘迫综合征中源自间充质干细胞的细胞外囊泡：当前文献综述及潜在的未来治疗选择
Clin Transl Med. 2019 Sep 12;8(1):25. doi: 10.1186/s40169-019-0242-9.
7
Trophic Effects of Mesenchymal Stem Cells in Tissue Regeneration.间充质干细胞在组织再生中的营养作用。
Tissue Eng Part B Rev. 2017 Dec;23(6):515-528. doi: 10.1089/ten.TEB.2016.0365.
8
Paracrine Mechanisms of Mesenchymal Stem Cells in Tissue Repair.间充质干细胞在组织修复中的旁分泌机制。
Methods Mol Biol. 2016;1416:123-46. doi: 10.1007/978-1-4939-3584-0_7.
9
Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial.间充质干细胞（基质）治疗 ARDS：1 期临床试验。
Lancet Respir Med. 2015 Jan;3(1):24-32. doi: 10.1016/S2213-2600(14)70291-7. Epub 2014 Dec 17.
10
Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study.异体脂肪间充质干细胞治疗急性呼吸窘迫综合征的随机、安慰剂对照初步研究。
Respir Res. 2014 Apr 4;15(1):39. doi: 10.1186/1465-9921-15-39.
Zotero 插件